BridgeMD
New treatment option for Age Related Macular Degeneration
Official title Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants
ClinicalTrials.gov ID: NCT04697095
What this study is testing
- What it's testing
- Age-related macular degeneration (AMD) affects 2 million people in France and is the main cause of irreversible blindness in France. All patients initially have an early form of the disease.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 15 and older
You may be able to join if
- General criteria:
- Male or female older than 50,
- Provide written informed consent,
- Patient affiliated to French social security,
- Maximum sampling volume (care + research) per 30-day period to be adapted according to the weight of the patient Specific criteria: Patient...
You likely can't join if
- General criteria:
- Patient whose weight is less than 50kg,
- Adult patient under guardianship or curatorship or unable to express consent,
- Person deprived of liberty,
- Patient participating in an ongoing clinical trial during the inclusion visit, Specific criteria:
- Patient with atrophic AMD in one eye and exudative AMD in the other eye,
See the full eligibility criteria
- General criteria:
- Male or female older than 50,
- Provide written informed consent,
- Patient affiliated to French social security,
- Maximum sampling volume (care + research) per 30-day period to be adapted according to the weight of the patient Specific criteria: Patient presenting in both eyes:
- Either the same type of AMD defined according to the modified international AREDS study (Ferris et al. 2013),
- or early AMD in one eye and atrophic AMD in the other eye, the patient will therefore be defined as being atrophic
- or early AMD in one eye and exudative AMD in the other eye, the patient will therefore be defined as exudative,
- or no retinal pathology (control group).
- General criteria:
- Patient whose weight is less than 50kg,
- Adult patient under guardianship or curatorship or unable to express consent,
- Person deprived of liberty,
- Patient participating in an ongoing clinical trial during the inclusion visit, Specific criteria:
- Patient with atrophic AMD in one eye and exudative AMD in the other eye,
- Patient presenting with chronic retinal pathologies other than AMD, defined according to the modified international AREDS study (Ferris et al. 2013) , in the included eye,
- Patient taking systemic drugs with an immunomodulatory action: immunosuppressants, immunomodulators, chemotherapy or corticosteroids,
- Patient with systemic pathologies modifying their immune status,
- Patient with a history of diabetes,
- Patient who had dynamic phototherapy on the included eye.
The study team makes the final eligibility decision.
Where it's taking place
- Lyon, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 15 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lyon, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.